News
BofA lowers rating of Novo Nordisk after Wegovy-maker issues profit warning
Investing.com - Novo Nordisk (NYSE:NVO)’s weight-loss and diabetes drugs Wegovy and Ozempic could face increased pressure in the future, weighing on the Danish pharmaceutical group’s earnings, according to analysts at BofA Securities.
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Cosmetic surgeons are reporting a growing number of patients with sagging skin and facial hollowing after losing weight with ...
Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...
Novo Nordisk A/S (NYSE:NVO), the Danish pharmaceutical giant renowned for its weight-loss drug Wegovy and diabetes treatment ...
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
Wegovy comes in higher doses than Ozempic and, therefore, can be more effective for weight loss. We’ll go deeper into how Wegovy and Ozempic work, their side effects and the costs of each ...
Today’s Forbes Daily covers Pacific tsunami activity after powerful quake, Trump breaks with Netanyahu over Gaza, the Forbes 50 Over 50, a railroad merger and more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback